melanoma oncologist @mskcancercenter I clinical trials, cellular therapy & translational immunotherapy research | n.b.: personal account
New York, NY
Joined August 2010
- Tweets809
- Following903
- Followers977
- Likes43.2K
so proud of superstar future oncology fellow @MiaAndreoli for leading this effort!
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma | JCO Oncology Practice ascopubs.org/doi/10.1200/OP-…
Jim Smithy retweeted
This is a landmark moment in melanoma, cancer immunology, & IO drug development at large. Checkpoint inhibitors have allowed us to uncover & amplify the immune impact of cancer therapies we used for decades (e.g.,chemo, RT). Now, coupled with the powerful mRNA vaccine technology, finally unlocked the potential for personalized immunotherapy. Congrats to @Merck & @moderna_tx Grateful for our patients & research teams that allowed to participate in such a monumental accomplishment!
A promising step forward in melanoma treatment. 🧬💙
Merck and Moderna announced positive Phase 3 results from the INTerpath-001 trial, showing that an investigational, personalized mRNA-based therapy, intismeran autogene (V940), combined with KEYTRUDA, significantly improved recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone in people with completely resected stage IIB-IV melanoma.
This is the first positive Phase 3 readout for an individualized neoantigen therapy and marks an important milestone for personalized cancer treatment. The therapy is designed using the unique genetic “fingerprint” of each patient’s tumor to help train the immune system to recognize and fight cancer cells.
The study will continue to evaluate overall survival, and the full data will be presented at an upcoming medical meeting and shared with regulators.
For people facing melanoma, every advance matters. Every breakthrough brings us closer to a future where more people can live longer—and live melanoma-free. 💙
merck.com/news/merck-and-mod…
#Melanoma #MelanomaResearch #CancerResearch #Immunotherapy #mRNA #ClinicalTrials
Jim Smithy retweeted
Happy to share our collaboration led by @jsmithymd across 14 international centers on this study of ICI after progression on TIL in advanced #melanoma.
➡️Post-TIL ICI activity was limited, with ORR 11% and median OS 8.8 months, underscoring the need for novel trials in this setting.
New #JITC short report: "Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma" jitc.bmj.com/content/14/6/e0…
@DrBetofMDPhD @ShirlyGrynberg @ajsfurness @ja_ocejo @bbuchbinderMD @LutzkyJose
@evanlipson @DoniaMarco @HaanenJohn
Jim Smithy retweeted
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. nbcnews.com/health/cancer/pe…
*fantastic* PFS data for darovasertib & crizotinib in HLA A 02:01 negative metastatic uveal melanoma —huge step forward in an area with immense unmet need 👏🏼 👏🏼 👏🏼 #ASCO26
Jim Smithy retweeted
Today at #ASCO26: MSK’s @jsmithymd shared his rapid oral abstract “A phase 2 trial of IO102-IO103 and nivolumab-relatimab in previously untreated, unresectable #melanoma.” – at Chicago, IL
Jim Smithy retweeted
Join MSK melanoma medical oncologist Dr. @jsmithymd at #ASCO26 as he presents results from a phase 2 trial evaluating IO102-IO103 in combination with nivolumab-relatlimab in patients with previously untreated, unresectable melanoma.
🕒 Saturday, May 30 | 5:36 p.m. CDT
Learn more: bit.ly/4u73WQz
a translational tour de force covering the last 15 years in melanoma therapy by dr antoni ribas; immense progress but still lots of work to do 🧬 🧫 @MSKCancerCenter
Jim Smithy retweeted
𝗧𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗗𝗮𝘆 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 continues with a series of expert-led sessions and presentations, featuring leading clinicians and researchers who highlight emerging therapies, share real-world clinical insights, and explore strategies to advance early detection and improve outcomes in melanoma care worldwide.
𝗝𝗮𝗺𝗲𝘀 𝗦𝗺𝗶𝘁𝗵𝘆(@jsmithymd) discussed emerging cell therapy platforms for advanced melanoma, highlighting innovative adoptive cell therapies and next-generation immune-based strategies that are expanding treatment possibilities for patients with refractory disease.
𝗭𝘂𝗹𝗳𝗶𝗾𝘂𝗲𝗿 𝗢𝘁𝘁𝘆 reviewed current approaches to first-line therapy of metastatic melanoma, focusing on treatment selection, immunotherapy combinations, and factors guiding personalized management in clinical practice.
𝗔𝘅𝗲𝗹 𝗛𝗮𝘂𝘀𝗰𝗵𝗶𝗹𝗱 shared perspectives on how melanoma is treated across Europe, outlining regional practices, evolving therapeutic standards, and the integration of novel systemic therapies into routine care.
𝗭𝗮𝗵𝗿𝗮 𝗠𝗼𝗵𝗮𝗺𝗲𝗱 𝗔𝗵𝗺𝗲𝗱 explored the challenges encountered when clinical guidelines meet real-world practice, emphasizing practical decision-making, resource considerations, and adapting evidence-based recommendations to diverse patient settings.
More insights continue to emerge as the OncoDaily Global Symposium unfolds 🌍
🔴 Live sessions available here:
youtube.com/live/7TDHWCyn724…
xitter.gq/i/broadcasts/1nxnRYQeA…
#OncoDaily #Cancer #Oncology
looking forward to a great day of discussion on solid tumor cell therapy at iwCART & sharing updates on PRAME-targeted TCR-T in advanced melanoma
Jim Smithy retweeted
Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. ja.ma/4167rLa
Jim Smithy retweeted
I wrote about the ambiguity in prognosis of a stage IV cancer diagnosis nowadays and the bravery our patients exhibit when they navigate that ambiguity every day. @NEJM
nejm.org/doi/10.1056/NEJMp25…
Jim Smithy retweeted
Ellen was diagnosed with a rare and hard to treat #ovariancancer. Everything changed when she enrolled in a clinical trial led by Dr. Rachel Grisham, based on a lab discovery years ago by @DSolit.
Watch more #SavedbyScience stories on YouTube: bit.ly/3ZLODjv
that’s a wrap on melanoma bridge! three days tackling the most pressing questions in the field with an inspiring roster of speakers… thank you @PAscierto & colleagues for organizing
Jim Smithy retweeted
More than a year after receiving a type of immunotherapy called tumor-infiltrating lymphocyte (#TIL) therapy, Pattie is doing well and has almost no signs of metastatic #melanoma
Learn more from @jsmithymd, a melanoma medical oncologist and cellular therapist at MSK and expert in #TILtherapy.
bit.ly/3X9yBP0
Jim Smithy retweeted
Published by @OncNewsCentral | I had a great conversation with Dr @jsmithymd & Dr Michael Postow on the latest in #Melanoma #Immunotherapy & #MolecularlyTargetedTherapy - Navigating Options
@MoffittNews
@MSKCancerCenter
oncologynewscentral.com/vide…
Jim Smithy retweeted
Scientists conducting medical research are facing an existential crisis: Layoffs and budget cuts pushed by President Trump that, they say, jeopardize finding a cure for cancer.
Ted Koppel talks with cancer patients taking part in clinical trials for treatments and vaccines, whose own contributions to finding a cure are imperiled.
Jim Smithy retweeted
🎥@jsmithymd of @MSKCancerCenter highlights the need for careful post-discharge monitoring of patients with melanoma treated with lifileucel due to risks of cytopenias. Tailored follow-up is key:
🔗 ow.ly/qver50WgfE3
@ASCO #ASCO25 #Melsm #Skcsm #ImmunoOnc
Jim Smithy retweeted
Underway now in the #melanoma rapid oral abstract session at #ASCO25: Sarah E. Lochrin, MBBCh (@LochrinSarah) from @MSKCancerCenter shares interim results from the C-IT Neo trial on single-dose neoadjuvant ipilimumab + nivolumab in resectable melanoma, with CD8+ PET imaging.
➡️ 59% major pathologic response after one dose
➡️ Grade ≥3 treatment-related AEs in just 9%
➡️ CD8+ PET tracer uptake correlated with IHC, but not predictive of response
#Immunotherapy #Neoadjuvant @ASCO #MoffittASCO25
Jim Smithy retweeted
Congratulations to Kathryn Arbour @KCArbourMD and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. @MSKCancerCenter
